We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

274 hedge funds and large institutions have $2.86B invested in Pacific Biosciences in 2023 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 104 increasing their positions, 75 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

146% more call options, than puts

Call options by funds: $54M | Put options by funds: $22M

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

39% more repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 75

30% more capital invested

Capital invested by funds: $2.2B → $2.86B (+$669M)

4.8% more ownership

Funds ownership: 104.41% → 109.21% (+4.8%)

9% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 45

0% more funds holding

Funds holding: 274 → 274 (0)

Holders
274
Holders Change
–
Holders Change %
0%
% of All Funds
3.99%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
49
Increased
104
Reduced
75
Closed
45
Calls
$54M
Puts
$22M
Net Calls
+$32M
Net Calls Change
-$44.1M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$163M
2
AIM
ARK Investment Management
Florida
+$38.3M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$28.7M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$23.8M
5
JSP
Jackson Square Partners
California
+$22.7M

Top Sellers

1
FCM
Farallon Capital Management
California
-$33M
2
Citadel Advisors
Citadel Advisors
Florida
-$21.3M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$10M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$9.78M
5
BBA
Baker Bros. Advisors
New York
-$9.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
IHAM
276
Integral Health Asset Management
New York
– -$6.68M -800,000 Closed
AAP
277
Ardsley Advisory Partners
Connecticut
– -$5.86M -701,500 Closed
PVI
278
Pura Vida Investments
New York
– -$3.47M -415,000 Closed
Voloridge Investment Management
279
Voloridge Investment Management
Florida
– -$3.23M -386,690 Closed
Qube Research & Technologies (QRT)
280
Qube Research & Technologies (QRT)
United Kingdom
– -$2.76M -330,331 Closed
Balyasny Asset Management
281
Balyasny Asset Management
Illinois
– -$2.73M -326,770 Closed
Renaissance Technologies
282
Renaissance Technologies
New York
– -$2.73M -326,622 Closed
Squarepoint
283
Squarepoint
New York
– -$2.07M -247,861 Closed
PHP
284
Parkman Healthcare Partners
Connecticut
– -$1.76M -210,580 Closed
N
285
Numerai
California
– -$1.56M -186,635 Closed
Millennium Management
286
Millennium Management
New York
– -$1.26M -153,717 Closed
SG Americas Securities
287
SG Americas Securities
New York
– -$1.22M -145,614 Closed
HF
288
HRT Financial
New York
– -$1.12M -134,188 Closed
BAMF
289
BI Asset Management Fondsmaeglerselskab
Denmark
– -$858K -102,765 Closed
SC
290
Shay Capital
New York
– -$626K -75,000 Closed
HSA
291
Hussman Strategic Advisors
Maryland
– -$438K -52,500 Closed
DFCM
292
Dark Forest Capital Management
Puerto Rico
– -$365K -43,698 Closed
PMEF
293
Point72 Middle East FZE
United Arab Emirates
– -$295K -35,306 Closed
AIM
294
Aigen Investment Management
New York
– -$290K -34,671 Closed
Verition Fund Management
295
Verition Fund Management
Connecticut
– -$266K -31,800 Closed
SCA
296
Snowden Capital Advisors
New York
– -$243K -29,116 Closed
GCM
297
Ghisallo Capital Management
Massachusetts
– -$209K -25,000 Closed
DA
298
Duality Advisers
Florida
– -$184K -22,075 Closed
Allspring Global Investments
299
Allspring Global Investments
North Carolina
– -$175K -20,962 Closed
DC
300
Diametric Capital
Massachusetts
– -$174K -20,837 Closed
9 10 11
12
13

PACB Hedge Fund Activity: Q4 2023 in Review

274 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2023, worth a combined $2.86B — up 30% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new PACB positions and 45 closed out — a net gain of 4 holders — while 104 added to existing stakes and 75 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $163M. The largest seller was Farallon Capital Management, cutting an estimated $33M.

  • 274 institutional investors held Pacific Biosciences (PACB) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $2.86B of Pacific Biosciences stock for Q4 2023, up 30% quarter-over-quarter.
  • 49 funds opened new Pacific Biosciences positions in Q4 2023 and 45 closed out, a net change of +4 holders.
  • The largest Pacific Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $163M added.
  • The largest Pacific Biosciences seller in Q4 2023 was Farallon Capital Management, an estimated $33M sold.

Based on aggregated 13F filings for Q4 2023.